NEOGHealthcare · Medical DevicesThe 4 Wall Street analysts covering Neogen Corp. hold a median 12-month price target of $13 — +11.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 15 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Neogen Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (87): Analysts have, on balance, been raising their forecasts.
Quality (55): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Size (33): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on NEOG, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +11.6% from it.
Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 3 Aug 2026 | Piper Sandler | Reiterates | Neutral | $11 → $13 |
| 12 Jan 2026 | Piper Sandler | Reiterates | Neutral | — |
| 12 Jan 2026 | Piper Sandler | Reiterates | Neutral | $6.50 → $10 |
| 9 Jan 2026 | Guggenheim | Maintains | Buy | — |
| 9 Jan 2026 | Guggenheim | Maintains | Buy | $8.00 → $12 |
| 10 Dec 2025 | CJS Securities | Upgrade | Market Outperform | — |
| 16 Oct 2025 | Piper Sandler | Reiterates | Neutral | — |
| 29 Sept 2025 | CJS Securities | Initiates | Market Perform | — |
| 29 July 2025 | William Blair | Downgrade | Market Perform | — |
| 30 June 2025 | Guggenheim | Maintains | Buy | — |
| 22 Apr 2025 | Piper Sandler | Maintains | Neutral | — |
| 14 Apr 2025 | Piper Sandler | Maintains | Neutral | — |
| 10 Apr 2025 | Guggenheim | Maintains | Buy | — |
| 21 Jan 2025 | Piper Sandler | Reiterates | Neutral | — |
| 19 Dec 2024 | Guggenheim | Initiates | Buy | — |
| 6 Aug 2024 | Piper Sandler | Maintains | Neutral | — |
| 15 Apr 2024 | Piper Sandler | Maintains | Neutral | — |
| 18 Jan 2024 | Piper Sandler | Maintains | Neutral | — |
| 16 Oct 2023 | Piper Sandler | Maintains | Neutral | — |
| 14 Aug 2023 | Wells Fargo | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NEOG appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 1% of US stocks
Cheaper than 43% of US stocks
Cheaper than 67% of US stocks
Cheaper than 8% of US stocks
Higher than 28% of US stocks
Higher than 35% of US stocks
Higher than 60% of US stocks
Higher than 47% of US stocks
Higher than 29% of US stocks
Higher than 43% of US stocks
Higher than 42% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Neogen Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research reported that Neogen (NEOG) shares have started gaining and may continue rising, based on strong earnings estimate revisions.
Why it matters — A NEOG watcher would care because upward earnings estimate revisions are often viewed as a signal that the company's financial outlook is improving.
Zacks Investment Research published a comparison of Perrigo (PRGO) and Neogen (NEOG), two Medical - Products stocks, examining which may be the better value option for investors seeking undervalued stocks. The article presents a value-focused analysis of both companies.
Why it matters — NEOG watchers would be interested in how the company is assessed against a peer in a widely read valuation comparison, which could influence investor perception.
Neogen Corporation published the transcript of its Q4 2026 earnings call, covering the company's financial results and business discussion for the quarter.
Why it matters — The earnings call transcript provides Neogen watchers with direct insight into management's commentary on the company's quarterly performance and outlook.
Zacks reported that Neogen's headline Q4 earnings numbers for the quarter ended May 2026 offer insight into the company's performance, and suggested it may be useful to compare key metrics against Wall Street estimates and prior-year actuals.
Why it matters — A NEOG watcher would care because comparing the company's quarterly results to consensus estimates and year-ago figures helps assess whether performance is meeting market expectations.
Neogen (NEOG) reported quarterly earnings of $0.09 per share, beating the Zacks Consensus Estimate of $0.05 per share, and up from $0.05 per share in the same quarter a year ago.
Why it matters — The earnings beat and year-over-year earnings growth may signal improving financial performance for Neogen.
The 4 Wall Street analysts covering Neogen Corp. have a median 12-month price target of $13, with estimates ranging from $12 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering Neogen Corp., 2 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Neogen Corp. 96 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 15 Aug 2026, Neogen Corp. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (87 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +11.6% from the last close, and Ticker Nerd's factor model ranks Neogen Corp. 96 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Neogen Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NEOG are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $14 over the next 12 months.
Neogen Corp. returned +111.8% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Neogen Corporation develops, manufactures, and markets products and services dedicated to food and animal safety worldwide. Operating through two primary segments, Food Safety and Animal Safety, the company provides diagnostic test kits, dehydrated culture media, and complementary solutions to detect foodborne pathogens, spoilage organisms, natural toxins, food allergens, drug residues, pesticide residues, and sanitation issues in human food and animal feed.
The most recent item we track (Zacks Investment Research, 11 Aug 2026): "Surging Earnings Estimates Signal Upside for Neogen (NEOG) Stock". Zacks Investment Research reported that Neogen (NEOG) shares have started gaining and may continue rising, based on strong earnings estimate revisions.
Neogen Corporation develops, manufactures, and markets products and services dedicated to food and animal safety worldwide. Operating through two primary segments, Food Safety and Animal Safety, the company provides diagnostic test kits, dehydrated culture media, and complementary solutions to detect foodborne pathogens, spoilage organisms, natural toxins, food allergens, drug residues, pesticide residues, and sanitation issues in human food and animal feed. In the Animal Safety segment, Neogen offers veterinary instruments, pharmaceuticals, vaccines such as BotVax B for equine botulism, topicals, parasiticides, diagnostic products, rodent control, cleaners, disinfectants, insect control products, and genomics testing services. These offerings support contamination prevention, foodborne illness mitigation, livestock health, pet wellness, and biosecurity across agriculture, food production, and veterinary sectors. Founded in 1981 and headquartered in Lansing, Michigan, Neogen Corporation plays a vital role in enhancing global food security and animal health standards.
CEO Mr. Mikhael Nassif · 2,636 employees · United States · https://www.neogen.com